On December 16, 2022, Health Canada issued a notice to stakeholders regarding their proposal to amend the regulations for Biologic Drugs (Schedule D drugs) in Division 4, Part C, of […] Read More >>
Health Canada Update: Non-Medicinal Ingredient Labeling for Nonprescription Drug Products Clara di Tella, BSc, Pharm QA Regulatory Affairs Specialist Health Canada has released a notice to inform drug manufacturers/sponsors of […] Read More >>